Big Pharma is quietly stepping up to provide critical supplies of essential medicines, other health equipment, and skilled local personnel to areas of the Philippines devastated by Typhoon Haiyan this month. Although industry operations in the Philippines appear largely intact, most companies are working through global humanitarian aid organizations due to the logistical challenges created by the collapse of infrastructure on the ground.
Big Pharma is quietly stepping up to provide critical supplies of essential medicines, other health equipment, and skilled local personnel to areas of the Philippines devastated by Typhoon Haiyan this month. Although industry operations in the Philippines appear largely intact, most companies are working through global humanitarian aid organizations due to the logistical challenges created by the collapse of infrastructure on the ground. Actions have been largely unpublicized to date; PhRMA spokesman Mark Grayson tells Pharm Exec that this is more or less deliberate and is indicative of the industry’s overall desire to be “a willing and reliable partner in times of disaster.”
Typical of the response are decisions taken by GSK and Merck in the immediate aftermath of the typhoon’s landfall on November 8. GSK’s local affiliate has given a cash gift of approximately $25,000 to the Philippines Red Cross for food, water, blankets and shelter. In addition, the company is donating medicines and consumer health products to local aid networks; GSK’s primary humanitarian aid partner, AmeriCares, is airlifting consignments of GSK registered antibiotics from pre-positioned stocks.
Merck has made cash donations of $100,000 each to the American Red Cross, Save the Children and the International Rescue Committee, all for general relief. It has also established a company micro-site to provide a 100 per cent match for employee donations in support of the recovery efforts. Finally, staff are working with partners involved in the Merck Medical Outreach Program [MMOP] to evaluate specific product donations to address public health interventions as they arise.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.